EchoNous develops Kosmos, a compact AI-guided point-of-care ultrasound system that images the heart and other body regions. Kosmos uses deep-learning algorithms to help operators acquire images, label them, and automatically calculate measurements such as ejection fraction. The company says Kosmos delivers diagnostic-quality images comparable to larger, more expensive devices, and it ranked highly for overall image quality in an independent study of five handheld ultrasound devices. EchoNous has partnered with virtual-care company 19Labs to link Kosmos to a telehealth platform, aiming to expand care to underserved communities and improve ultrasound education with real-time virtual teaching. The Redmond, Wash.–based startup raised $7M in new funding noted in an SEC filing and confirmed by a company spokesperson. Prior financings cited in the article include a $57M Series D in September 2022 and $60M raised in September 2021. EchoNous markets Kosmos, a compact, AI-guided point-of-care ultrasound system that images the heart and other body regions. Its deep-learning algorithms assist operators in collecting high-quality images, labeling them, and automatically calculating measurements such as ejection fraction. Kosmos was rated highly for overall image quality in an independent study comparing five hand-held devices. The company is also developing the Lexsa ultrasound probe, which received 510(k) clearance last year to enable nerve, lung, vascular and musculoskeletal bedside ultrasound. Recent product and partnership activity includes a deal with Samsung to pair Kosmos with a Samsung tablet. EchoNous was launched in 2015, is based in Redmond, Wash., and has about 150 employees. EchoNous develops Kosmos, an AI-guided point-of-care ultrasound (POCUS) system that provides diagnostic-quality imaging. Kosmos is a handheld POCUS device offering continuous-wave Doppler capability and enables systolic heart function assessment, features with important cardiology applications. The system is designed for AI guidance and meets HIPAA requirements for data collection, storage, and transmission. EchoNous was founded in 2016 and is led by CEO Kevin Goodwin. The company intends to accelerate the commercial launch of Kosmos using newly raised funds. It raised $60M in a financing that combines senior secured debt and equity from Kennedy Lewis Investment Management. EchoNous builds compact ultrasound devices under its Signostics business, applying artificial intelligence, including deep and machine learning, to measure bladder volume and bladder wall thickness. Its core product, Uscan, is a miniaturized AI ultrasound tool for bladder and kidney care with regulatory approvals in the U.S., Australia, Canada, Europe, Singapore and Japan, and the company exports globally. Management is led by Kevin Goodwin (CEO) and Niko Pagoulatos, PhD (COO & CIO). The company intends to use recent funding to continue market conversion of Uscan, advance a nursing tool with a vein-finding solution, and bring a major new AI-driven ultrasound project to market. EchoNous raised $35m in the reported financing, which the company will deploy against those commercial and development priorities.

Total raised

$159M

Funding rounds

5

Latest round

Equity

Latest activity

Jul 2023